UK biotech Ikarovec has entered into an exclusive worldwide option agreement to use VectorBuilder’s novel AAV capsid technology in combination with preclinical gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD).
VectorBuilder’s proprietary capsid technology will allow IKAR-003 to be delivered to the eye via the minimally invasive intravitreal route in a doctor’s office. This will enhance access to the treatment for the target patient population — those at the earlier, intermediate AMD stage for whom prevention of disease progression is a priority.
IKAR-003 is designed to prevent disease progression through a one-time injection of an AAV-delivered dual-pathway gene therapy combining neuroprotection and complement modulation to preserve visual function.
Based on the potential of IKAR-003 in intermediate AMD, the proposed deal is expected to be worth in excess of $1 billion.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!